Simnova Biotechnology develops chimeric antigen receptor-engineered natural killer (CAR-NK) cell therapies targeting cancer, specifically focusing on hematological and solid tumors. Their products aim to provide effective, low-cost treatment options for patients, with demonstrated superior anti-tumor effects and extended remission durations compared to traditional therapies.
Funding
$27.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments, including traditional CAR-T therapies, can be expensive, have limited efficacy for solid tumors, and may result in significant side effects, including cytokine release syndrome and neurotoxicity. Autologous CAR-T therapies also require patient-specific manufacturing, which increases cost and turnaround time.
Solution
Simnova Biotechnology develops allogeneic, "off-the-shelf" CAR-NK (chimeric antigen receptor-engineered natural killer) cell therapies designed to overcome the limitations of existing cancer treatments. Their CAR-NK platform leverages engineered NK cells to target both hematological and solid tumors, offering a potentially more effective and safer alternative to traditional CAR-T cell therapies. Simnova's innovative CAR structure design and stable CMC (Chemistry, Manufacturing, and Controls) capabilities enable large-scale production of universal NK cell products with enhanced anti-tumor activity and extended remission durations. The company's allogeneic approach aims to provide readily available, cost-effective treatment options for a broader range of cancer patients.
Target Audience
The primary target audience includes patients with hematological and solid tumors who are seeking more effective, accessible, and potentially safer treatment options, as well as oncologists and hematologists looking for innovative cell therapies to improve patient outcomes.
Features
- Allogeneic CAR-NK cell therapy platform for "off-the-shelf" availability
- Proprietary CAR structure design with enhanced anti-tumor efficacy
- Targeting both hematological malignancies and solid tumors
- Mature and scalable CMC process for large-scale NK cell production
- High CAR transduction efficiency, expansion rate, and cell activity post-cryopreservation
- Potential for reduced toxicity compared to CAR-T therapies
- BiTE CAR-T platform for solid tumor applications